By Gabrielle Masson
Jul 7, 2022 02:27pm
Adverum Biotechnologies is showing 78 employees the door as part of a new restructuring plan that bets it all on a wet age-related macular degeneration treatment candidate called ixo-vec. (iStock / Getty Images Plus)
Adverum Biotechnologies is slashing its workforce by nearly 40%, cutting 78 employees under a new restructuring plan that will funnel resources to ixo-vec, a wet age-related macular degeneration (AMD) treatment candidate.
The gene therapy biotech's shares have actually risen since the news broke yesterday—perhaps because the announcement was buried between clinical news that included an FDA green light to start testing ixo-vec in humans. Shares were sitting at just under $1.40 apiece Thursday afternoon, up about 15% compared to a previous close of $1.23.
The California biotech is cutting costs to prioritize the clinical development of ixo-vec, a single intravitreal injection and focus on prevalent eye diseases, said Laurent Fischer, M.D., Adverum president and CEO. The biotech is preparing to start a phase 2 trial, dubbed LUNA, for ixo-vec.
Less than a year ago, the biotech terminated its study assessing the same drug, known at the time as ADVM-022, in diabetic macular edema (DME) because of a dose-limiting toxicity—meaning the dose can’t be escalated due to side effects.
The biotech forged ahead with the drug in wet AMD, but the DME failure wiped out nearly half of the biotech’s pipeline, RBC Capital Markets analysts said last July.
While the cause of the toxicity is unknown, DME patients often have multiple comorbidities not seen in wet AMD. Adverum, which has no other clinical-phase assets, has limited options if ixo-vec doesn't find success in wet AMD.
The restructuring will extend the company’s expected cash runway by a year into 2025. As of March 31, the biotech had $271.1 million in cash, cash equivalents and short-term investments, Fischer said.
Adverum expects the layoffs to cut yearly operating costs by $15.3 million while the restructuring itself will cost around $4.2 million, according to a Securities and Exchange Commission filing. Adverum anticipates finishing the restructuring process in the fourth quarter of this year.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent ADVM News
- Adverum Biotechnologies to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates • GlobeNewswire Inc. • 03/18/2024 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/04/2024 09:40:18 PM
- Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/22/2024 08:47:57 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/21/2024 08:39:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 09:17:58 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:26:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:33:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:27:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:38 PM
- Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:50:28 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/09/2024 04:41:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:45:34 PM
- Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 10:03:11 PM
- Adverum Biotechnologies Announces $127.5 Million Private Placement Financing • GlobeNewswire Inc. • 02/05/2024 12:45:00 PM
- Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 • GlobeNewswire Inc. • 02/01/2024 10:30:00 PM
- Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:11:55 PM
- Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society • GlobeNewswire Inc. • 12/07/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM